A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.
No Comments »
Filed under: Pharmacy News
The US Food and Drugs Administration (FDA) and European Medicines Agency (EMA) are looking at the pros and cons of using Gilenya (fingolimod) in treating the neurological autoimmune disease Multiple Sclerosis (MS).
No Comments »
Filed under: Pharmacy News
Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn’s disease.
No Comments »
Filed under: Pharmacy News
Today Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis.
No Comments »
Filed under: Pharmacy News
Researchers utilizing an advanced magnetic resonance imaging (MRI) technology to characterize and chart the evolution of MS lesions found that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE (glatiramer acetate injection) experienced significantly increased magnetization transfer ratio.
No Comments »
Filed under: Pharmacy News
(MedPage Today) — The death of a multiple sclerosis patient shortly after a first dose of fingolimod (Gilenya) is under review by the FDA, the agency said.
No Comments »
Filed under: General Health News
(MedPage Today) — The death of a multiple sclerosis patient shortly after a first dose of fingolimod (Gilenya) is under review by the FDA, the agency said.
No Comments »
Filed under: Pharmacy News
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a (Rebif®), an approved injectable therapy, in people with relapsing forms of multiple sclerosis (RMS)…
No Comments »
Filed under: Pharmacy News
Genzyme, a Sanofi company, today reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a, an approved injectable therapy, in people with relapsing forms of multiple sclerosis.
No Comments »
Filed under: Pharmacy News
The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s or Motor Neuron Disease.
No Comments »
Filed under: Pharmacy News
